BIBW 2992 in Patients With Advanced Solid Tumors
The primary objective was to collect safety data for BIBW 2992.
Neoplasms
DRUG: BIBW 2992
Incidence and severity of Adverse Events, according to Common Terminology Criteria (CTC) version 3, with particular scrutiny of events that were considered to be dose-limiting toxicities and those that were serious or significant, up to 18 months
Durability of non-progression as measured by tumor assessment according to Response Evaluation Criteria in Solid Tumors (RECIST), every 8 weeks up to 18 months
The primary objective was to collect safety data for BIBW 2992.